4.8 Article

Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer

期刊

CELL
卷 181, 期 7, 页码 1612-+

出版社

CELL PRESS
DOI: 10.1016/j.cell.2020.05.017

关键词

-

资金

  1. Parker Institute for Cancer Immunotherapy
  2. NIH [R01CA194511, R01CA223484, U01CA233100, U01CA244452, T32CA177555, K08AI139375]
  3. Conquer Cancer Foundation of the American Society of Clinical Oncology
  4. Bladder Cancer Advocacy Network Palm Beach New Discoveries Young Investigator Award
  5. Prostate Cancer Foundation Young Investigator Award
  6. Peter Michael Foundation
  7. Parker Institute of Cancer Immunotherapy
  8. Prostate Cancer Foundation

向作者/读者索取更多资源

Responses to anti-PD-1 immunotherapy occur but are infrequent in bladder cancer. The specific T cells that mediate tumor rejection are unknown. T cells from human bladder tumors and non-malignant tissue were assessed with single-cell RNA and paired T cell receptor (TCR) sequencing of 30,604 T cells from 7 patients. We find that the states and repertoires of CD8(+) T cells are not distinct in tumors compared with non-malignant tissues. In contrast, single-cell analysis of CD4(+) T cells demonstrates several tumor-specific states, including multiple distinct states of regulatory T cells. Surprisingly, we also find multiple cytotoxic CD4(+) T cell states that are clonally expanded. These CD4(+) T cells can kill autologous tumors in an MHC class II-dependent fashion and are suppressed by regulatory T cells. Further, a gene signature of cytotoxic CD4(+) T cells in tumors predicts a clinical response in 244 metastatic bladder cancer patients treated with anti-PD-L1.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据